First Trust NYSE Arca Biotechnology Index Fund
Latest First Trust NYSE Arca Biotechnology Index Fund News and Updates
Company & Industry Overviews How Xtandi Fueled Big Pharmaceutical Interest in Medivation
Xtandi is the major factor behind Pfizer’s (PFE) interest in Medivation (MDVN). The drug, along with MDVN’s pipeline molecules, should strengthen Pfizer’s (PFE) oncology franchise.Earnings Report How Much Does Biogen Spend on Research and Development?
Biogen’s (BIIB) R&D expenses for 4Q15 were $542 million, or 19% of its total revenue, including a $60 million payment to Mitsubishi Tanabe.Company & Industry Overviews ALNY Should Complete Revusiran’s Endeavour Trial Enrollment in Late 2016
If the Endeavour study results in positive data, Alnylam Pharmaceuticals may become a major rare disease player like its peers United Therapeutics (UTHR) and Vertex Pharmaceuticals.Earnings Report Regeneron Pharmaceuticals’ Major Revenue Sources in 4Q15
Regeneron Pharmaceuticals (REGN) earns revenue from net product sales, collaboration, and technology licenses.